Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer

Authors: Chris E. Adkins, Mohamed I. Nounou, Tanvirul Hye, Afroz S. Mohammad, Tori Terrell-Hall, Neel K. Mohan, Michael A. Eldon, Ute Hoch, Paul R. Lockman

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

Brain metastases are an increasing problem in women with invasive breast cancer. Strategies designed to treat brain metastases of breast cancer, particularly chemotherapeutics such as irinotecan, demonstrate limited efficacy. Conventional irinotecan distributes poorly to brain metastases; therefore, NKTR-102, a PEGylated irinotecan conjugate should enhance irinotecan and its active metabolite SN38 exposure in brain metastases leading to brain tumor cytotoxicity.

Methods

Female nude mice were intracranially or intracardially implanted with human brain seeking breast cancer cells (MDA-MB-231Br) and dosed with irinotecan or NKTR-102 to determine plasma and tumor pharmacokinetics of irinotecan and SN38. Tumor burden and survival were evaluated in mice treated with vehicle, irinotecan (50 mg/kg), or NKTR-102 low and high doses (10 mg/kg, 50 mg/kg respectively).

Results

NKTR-102 penetrates the blood-tumor barrier and distributes to brain metastases. NKTR-102 increased and prolonged SN38 exposure (>20 ng/g for 168 h) versus conventional irinotecan (>1 ng/g for 4 h). Treatment with NKTR-102 extended survival time (from 35 days to 74 days) and increased overall survival for NKTR-102 low dose (30 % mice) and NKTR-102 high dose (50 % mice). Tumor burden decreased (37 % with 10 mg/kg NKTR-102 and 96 % with 50 mg/kg) and lesion sizes decreased (33 % with 10 mg/kg NKTR-102 and 83 % with 50 mg/kg NKTR-102) compared to conventional irinotecan treated animals.

Conclusions

Elevated and prolonged tumor SN38 exposure after NKTR-102 administration appears responsible for increased survival in this model of breast cancer brain metastasis. Further, SN38 concentrations observed in this study are clinically achieved with 145 mg/m2 NKTR-102, such as those used in the BEACON trial, underlining translational relevance of these results.
Appendix
Available only for authorised users
Literature
1.
German RR, Fink AK, Heron M, Stewart SL, Johnson CJ, Finch JL, et al. The accuracy of cancer mortality statistics based on death certificates in the United States. Cancer Epidemiol. 2011;35(2):126–31.CrossRefPubMed
2.
3.
Guerin S, Laplanche A. [Statistics of mortality in 1994 and predictions of death caused by cancer 1997]. Presse Med. 1997;26(24):1149–53.PubMed
4.
Mera SL. Cancer mortality statistics in England and Wales. Med Lab Sci. 1992;49(3):232.PubMed
5.
Johnson RH, Chien FL, Bleyer A. Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA. 2013;309(8):800–5.CrossRefPubMed
6.
Soffietti R, Ruda R, Trevisan E. Brain metastases: current management and new developments. Curr Opin Oncol. 2008;20(6):676–84.CrossRefPubMed
7.
Flanigan JC, Jilaveanu LB, Chiang VL, Kluger HM. Advances in therapy for melanoma brain metastases. Clin Dermatol. 2013;31(3):264–81.CrossRefPubMed
8.
Tomasello F, La Torre D. Brain metastases: Can we do more? World Neurosurg. 2014;81(1):52-53.
9.
10.
Lechapt-Zalcman E, Karanian-Philippe M, Rousseau A. [Diagnosis of brain metastases: an update in 2012]. Bull Cancer. 2013;100(1):29–34.PubMed
11.
Hofer S, Pestalozzi BC. Treatment of breast cancer brain metastases. Eur J Pharmacol. 2013.
12.
Niwinska A, Olszewski W, Murawska M, Pogoda K. Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes. J Neurooncol. 2011;105(3):547–53.CrossRefPubMedPubMedCentral
13.
Caffo M, Barresi V, Caruso G, Cutugno M, La Fata G, Venza M, et al. Innovative therapeutic strategies in the treatment of brain metastases. Int J Mol Sci. 2013;14(1):2135–74.CrossRefPubMedPubMedCentral
14.
Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer. 2011;11(5):352–63.CrossRefPubMed
15.
Smith QR. Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system. Pharm Biotechnol. 1996;8:285–307.CrossRefPubMed
16.
17.
Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, et al. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin cancer res : an official journal of the American Association for Cancer Research. 2010;16(23):5664–78.CrossRef
18.
Regina A, Demeule M, Che C, Lavallee I, Poirier J, Gabathuler R, et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol. 2008;155(2):185–97.CrossRefPubMedPubMedCentral
19.
Serwer LP, Noble CO, Michaud K, Drummond DC, Kirpotin DB, Ozawa T, et al. Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts. Neuro Oncol. 2011;13(12):1288–95.CrossRefPubMedPubMedCentral
20.
Verreault M, Strutt D, Masin D, Anantha M, Waterhouse D, Yapp DT, et al. Irinophore C, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model. J controlled release : official journal of the Controlled Release Society. 2012;158(1):34–43.CrossRef
21.
Thomas FC, Taskar K, Rudraraju V, Goda S, Thorsheim HR, Gaasch JA, et al. Uptake of ANG1005, A Novel Paclitaxel Derivative, Through the Blood–brain Barrier into Brain and Experimental Brain Metastases of Breast Cancer. Pharm Res. 2009.
22.
Birngruber T, Raml R, Gladdines W, Gatschelhofer C, Gander E, Ghosh A, et al. Enhanced doxorubicin delivery to the brain administered through glutathione PEGylated liposomal doxorubicin (2B3-101) as compared with generic Caelyx,((R))/Doxil((R))--a cerebral open flow microperfusion pilot study. J Pharm Sci. 2014;103(7):1945–8.CrossRefPubMed
23.
Gaillard PJ, Appeldoorn CC, Dorland R, van Kregten J, Manca F, Vugts DJ, et al. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). PLoS One. 2014;9(1), e82331.CrossRefPubMedPubMedCentral
24.
Noble CO, Krauze MT, Drummond DC, Forsayeth J, Hayes ME, Beyer J, et al. Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors. Nanomedicine. 2014.
25.
Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. Ann oncol : official journal of the European Society for Medical Oncology / ESMO. 1995;6(2):141–51.
26.
Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343(13):905–14.CrossRefPubMed
27.
Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000;355(9209):1041–7.CrossRefPubMed
28.
Freyer G, Rougier P, Bugat R, Droz JP, Marty M, Bleiberg H, et al. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups. Br J Cancer. 2000;83(4):431–7.CrossRefPubMedPubMedCentral
29.
Raymond E, Fabbro M, Boige V, Rixe O, Frenay M, Vassal G, et al. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann oncol : official journal of the European Society for Medical Oncology / ESMO. 2003;14(4):603–14.CrossRef
30.
Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J clin oncol : official journal of the American Society of Clinical Oncology. 1999;17(5):1516–25.
31.
Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2006;8(2):189–93.CrossRefPubMedPubMedCentral
32.
Horowitz RW, Wadler S, Wiernik PH. A review of the clinical experience with irinotecan (CPT-11). Am J Ther. 1997;4(5–6):203–10.CrossRefPubMed
33.
Chabot GG. Clinical pharmacology and pharmacodynamics of irinotecan. A review. Ann N Y Acad Sci. 1996;803:164–72.CrossRefPubMed
34.
Wiseman LR, Markham A. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs. 1996;52(4):606–23.CrossRefPubMed
35.
Bonneterre J. Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan. Bull Cancer. 1995;82(8):623–8.PubMed
36.
Hoch U, Staschen CM, Johnson RK, Eldon MA. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol. 2014.
37.
Jameson GS, Hamm JT, Weiss GJ, Alemany C, Anthony S, Basche M, et al. A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin cancer res : an official journal of the American Association for Cancer Research. 2013;19(1):268–78.CrossRef
38.
Vergote IB, Garcia A, Micha J, Pippitt C, Bendell J, Spitz D, et al. Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer. J clin oncol : official journal of the American Society of Clinical Oncology. 2013;31(32):4060–6.CrossRef
39.
Awada A, Garcia AA, Chan S, Jerusalem GH, Coleman RE, Huizing MT, et al. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study. Lancet Oncol. 2013;14(12):1216–25.CrossRefPubMed
40.
Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs. 1996;7(1):78–86.CrossRefPubMed
41.
Kemper EM, van Zandbergen AE, Cleypool C, Mos HA, Boogerd W, Beijnen JH, et al. Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein. Clin cancer res : an official journal of the American Association for Cancer Research. 2003;9(7):2849–55.
42.
On NH, Mitchell R, Savant SD, Bachmeier CJ, Hatch GM, Miller DW. Examination of blood–brain barrier (BBB) integrity in a mouse brain tumor model. J Neurooncol. 2012.
43.
Adkins CE, Nounou MI, Mittapalli RK, Terrell-Hall TB, Mohammad AS, Jagannathan R, et al. A novel preclinical method to quantitatively evaluate early-stage metastatic events at the murine blood–brain barrier. Cancer prev res. 2015;8(1):68–76.CrossRef
44.
45.
Mittapalli RK, Liu X, Adkins CE, Nounou MI, Bohn KA, Terrell TB, et al. Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model. Mol Cancer Ther. 2013;12(11):2389–99.CrossRefPubMed
46.
Lin NU, Amiri-Kordestani L, Palmieri D, Liewehr DJ, Steeg PS. CNS metastases in breast cancer: old challenge, new frontiers. Clin cancer res : an official journal of the American Association for Cancer Research. 2013;19(23):6404–18.CrossRef
47.
Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol. 2010;624:25–37.CrossRefPubMed
48.
Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55(17):3752–6.PubMed
49.
Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013;65(1):71–9.CrossRefPubMed
50.
Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1):6387–92.PubMed
51.
52.
Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348(25):2491–9.CrossRefPubMed
53.
Liu J, Yu M, Zhou C, Yang S, Ning X, Zheng J. Passive Tumor Targeting of Renal-Clearable Luminescent Gold Nanoparticles: Long Tumor Retention and Fast Normal Tissue Clearance. J Am Chem Soc. 2013.
54.
Nakagawa H, Groothuis DR, Owens ES, Fenstermacher JD, Patlak CS, Blasberg RG. Dexamethasone effects on [125I]albumin distribution in experimental RG-2 gliomas and adjacent brain. J cereb blood flow metab : official journal of the International Society of Cerebral Blood Flow and Metabolism. 1987;7(6):687–701.CrossRef
55.
Adkins CE, Mittapalli RK, Manda VK, Nounou MI, Mohammad AS, Terrell TB, et al. P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model. Front pharmacol. 2013;4:136.CrossRefPubMedPubMedCentral
56.
Bansal T, Mishra G, Jaggi M, Khar RK, Talegaonkar S. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. Eur j pharm sci : official journal of the European Federation for Pharmaceutical Sciences. 2009;36(4–5):580–90.CrossRef
57.
58.
Zabaleta V, Ponchel G, Salman H, Agueros M, Vauthier C, Irache JM. Oral administration of paclitaxel with pegylated poly(anhydride) nanoparticles: permeability and pharmacokinetic study. Eur J Pharm Biopharm. 2012;81(3):514–23.CrossRefPubMed
59.
Hugger ED, Audus KL, Borchardt RT. Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. J Pharm Sci. 2002;91(9):1980–90.CrossRefPubMed
60.
Sane R, Agarwal S, Elmquist WF. Brain distribution and bioavailability of elacridar after different routes of administration in the mouse. Drug metab dispos: the biological fate of chemicals. 2012;40(8):1612–9.CrossRef
61.
Kalvass JC, Polli JW, Bourdet DL, Feng B, Huang SM, Liu X, et al. Why Clinical Modulation of Efflux Transport at the Human Blood–brain Barrier Is Unlikely: The ITC Evidence-Based Position. Clin Pharmacol Ther. 2013.
Metadata
Title
NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer
Authors
Chris E. Adkins
Mohamed I. Nounou
Tanvirul Hye
Afroz S. Mohammad
Tori Terrell-Hall
Neel K. Mohan
Michael A. Eldon
Ute Hoch
Paul R. Lockman
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1672-4

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue

Research article

Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients

Research article

Effects of payer status on breast cancer survival: a retrospective study

Research article

Diagnostic intervals before and after implementation of cancer patient pathways – a GP survey and registry based comparison of three cohorts of cancer patients

Study protocol

Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management

Research article

MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation

Research article

Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits